Aleksandra Djokovic

Proud to share the publication of the Serbian (RS) SCAD Registry 🇷🇸 — the first multicenter SCAD registry from an underrepresented Eastern European region. Among 123 patients:• 85% women• HTN 49.6%, smoking 41.5%• PCI in 51.3%• In-hospital MACE 23.6% #SCAD #Cardiology #WIC

Professor Cecilia Linde - the winner of the Gold medal of the Serbian Heart Failure Society at CardioS 2026 and the ESC Summit of Eastern Countries, Belgrade, Serbia, March 27, 2026

Cardiovascular disorders in women: from HF and VHD to microcirculatory dysfunction in IHD. Great CME at the Faculty of Medicine, BU. Many thanks to all participants, fabulous faculty and my co-organizers, @saskavaska Aleksandra Djokovic & @MarkoBanovic80 Marko Banovic

Successful session at #SINERGY2025 on PRAMIRS – the 1st premature AMI registry in Serbia & South Europe. Preliminary data: young AMI patients (≤45y) are mostly male, obese, smokers with hyperlipidemia, STEMI & obstructive CAD, with marked gender disparities. @GoranEBC

Honored to co-chair today’s #ESCCongress session in Madrid on Autoimmune disorders, inflammation & cardiovascular disease. Great talks on RA, CT imaging, psoriasis & systemic inflammation. Thanks to the speakers & audience for the lively discussion! 💙

In PROSPECT II, elevated TC, LDL-C, & non-HDL-C were strongly associated w/ pancoronary atherosclerosis & lipid deposition, whereas elevated Lp(a) was strongly associated w/ the presence of focal vulnerable plaques. Get more details: bit.ly/43lbEMP #JACC @JACCJournals

🫀 Top 10 Updates from #HeartFailure2025 Congress! Here’s what every cardiologist & healthcare provider needs to know about the latest in heart failure treatment and management: 👇🧵 [1/11]

Age-specific troponin thresholds: considerations for the fifth universal definition of myocardial infarction in EHJ. doi.org/10.1093/eurhea… @ESCardio @ESC_Journals #age #5UDMI @johnwmcevoy

I was honored to co-chair a brilliant session on rare causes of heart failure presented by amazing young colleagues. Always consider a broader HF differential— antiphospholipid sy, adverse effects of biologic therapies, EGPA. A truly eye-opening discussion! #HeartFailure2025

Excitement is ⬆️ as #HeartFailure2025 in vibrant Belgrade approaches! Join us onsite/online for an exceptional scientific experience, featuring 80 sessions, groundbreaking HF trials, and thought-provoking debates. Honored to be part of it and proud to welcome you to my hometown!

@Marta33717088 @PolovinaMarija @SvetlanaAposto4 @MilaKovaevi1 @escardio @WomenAs1 Honored to have the opportunity to exchange thoughts on female's CVD risk factors in young, on SCAD, on disparities in CVD trials... with you 🫂. Thanking @MilaKovaevi1 who made that happen ❤️

@saskavaska @PolovinaMarija @SvetlanaAposto4 @MilaKovaevi1 @escardio @WomenAs1 It was great pleasure to be a part of #BASICS+ 2025 🙏 tank you very much for the invitation and for organizing the session about #womenshealth

A session dedicated to women on #BASICs conference in Novi Sad, Serbia. Together with chair, and valuable member of Gender Disparities Committee of #EAPCI. The first results of our national PRematureAMI Registry of Serbia and SCADSerbia, underlined the need od such a committee

Inflammation fuels 🫀 disease—but what if we could stop it at the source? This #JACCAsia review explores how blocking CGAS-STING1 immune pathway could prevent cardiac dysfunction & improve survival. Game-changer for CV therapy? 🔍 jacc.org/doi/10.1016/j.… #cvPrev #CVD @AJMarianMD

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC onlinelibrary.wiley.com/doi/epdf/10.10…

🔴 ASE Recommendations for Evaluation of Prosthetic Valves with Echo & Doppler Ultrasound 🔹Normal Flow Patterns & Essential Parameters in the Evaluation Prosthetic Aortic Valves Prosthetic Mitral Valves Prosthetic Tricuspid Valves Prosthetic Pulmonic Valves

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA. WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA. STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes. API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients. RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months. FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery. REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding. HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent. SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns. ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension. DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.

The most fantastic knowledge quiz at CardioS 2025. Many thanks to our fabulous organizers @saskavaska Aleksandra Djokovic and MarinaOstojic and congrats to the happy winners 💪🍀👍😊

The first EuroIntervention issue of 2025 features a clinical consensus statement from the EAPCI, in collaboration with the @escardio Working Group on Cardiovascular Surgery, outlining procedural and technical requirements to enhance the efficacy and safety of PCI in high-risk patients on optimal medical therapy. These patients, deemed unsuitable for CABG by the Heart Team due to unacceptable surgical risks, may benefit from PCI for prognostic reasons (e.g., left main disease, last remaining vessel, or extensive ischemia). The statement emphasizes the importance of a multidisciplinary decision-making approach involving interventional cardiologists, cardiac surgeons, anesthetists, and heart failure experts to weigh the potential risks and futility of PCI. eurointervention.pcronline.com/article/high-r…

Are all stents the same for high bleeding risk (HBR) patients? BioFreedom, Resolute Onyx, Synergy, and Xience are approved for HBR patients by both the European Commission and FDA. While Orsiro Mission has strong evidence for HBR use, it lacks specific HBR regulatory approval. Ultimaster and Supraflex Cruz are not specifically labeled for HBR but are approved for short DAPT durations. We wrote a brief article on the topic of stent selection for HBR patients. tandfonline.com/doi/full/10.10…

@DFCapodanno Honestly, this post of yours made me feel so nice. Thank you! 💕

A fantastic patient, discharged on her own legs after days of battles and hardships, gifted us a plant with this message, to remind us—if we ever need reminding—that beautiful things happen when we work as a team: "What makes a plant wonderful is the combination of all its parts. In the same way, everything in life reflects the same principle. This is the memory I have of this ward. Thank you to each one of you." We will water it with care.